J&J Says Cancer Drug Study Sinks Bayer's False Ad Claims
Johnson & Johnson told a New York federal court that a peer-reviewed scientific journal's publication of a study on the active ingredient in its prostate cancer drug must end Bayer's claims...To view the full article, register now.
Already a subscriber? Click here to view full article